A new study found that a specially formulated version of cannabidiol (CBD) delivered approximately seven times more CBD into reconstructed human skin after 24 hours than a conventional oil-based formulation, while also substantially reducing markers associated with inflammation.
The research, published October 27 in the journal Cosmetics, was conducted by scientists at CIDETEC and the Biogipuzkoa Health Research Institute in Spain. Researchers developed a CBD formulation using a polypeptide-stabilized oil-in-water emulsion designed to improve the cannabinoid’s ability to penetrate the skin and maintain its biological activity.
CBD’s potential for treating skin inflammation has attracted increasing scientific attention, but its poor water solubility and tendency to accumulate in the skin’s outermost layer have limited its effectiveness in topical applications. The new delivery system was designed to overcome those barriers by encapsulating CBD in microscopic droplets capable of reaching deeper epidermal layers.
Using reconstructed human epidermal tissue, researchers compared the encapsulated CBD formulation with CBD dissolved in oil at equivalent concentrations. After six hours, the encapsulated formulation produced approximately 11 times greater CBD accumulation in the epidermis. After 24 hours, the difference remained substantial, with 33.63 micrograms of CBD detected in tissue treated with the encapsulated formulation compared with 4.77 micrograms in tissue treated with conventional CBD oil.
The formulation also demonstrated significant anti-inflammatory activity. In human skin cells exposed to ultraviolet B (UVB) radiation, encapsulated CBD reduced production of the inflammatory proteins IL-6 and IL-8 by 93% and 73%, respectively, compared with untreated irradiated cells. Conventional CBD produced smaller effects under the same experimental conditions.
Additional experiments using reconstructed human skin tissue showed that the encapsulated formulation reduced UVB-induced expression of four inflammation-related genes. IL-6 expression declined by 63%, IL-8 by 50%, IL-1B by 57% and TNF by 55%, compared with untreated irradiated tissue.
Researchers also found that the delivery system itself, even without CBD, exhibited some anti-inflammatory properties. In certain measurements, including IL-8 gene expression in reconstructed skin, the CBD-free formulation produced greater reductions than the CBD-containing version. This suggests that some of the observed benefits may be attributable to the carrier ingredients rather than CBD alone.
Beyond its anti-inflammatory effects, the formulation demonstrated considerable stability. It maintained its CBD content at approximately 175 milligrams per milliliter during 18 months of storage, with an encapsulation efficiency exceeding 99%. The researchers also found no evidence of irritation when the formulation was tested on reconstructed human epidermal tissue at the selected concentration.
However, the effects were concentration-dependent, with higher CBD concentrations reducing cell viability in laboratory testing.
The findings provide evidence that the way CBD is formulated can substantially influence its distribution and biological activity within the skin. Researchers emphasized that the experiments were conducted using cultured human cells and reconstructed skin tissue rather than human volunteers. The skin penetration measurements were also conducted in duplicate, preventing statistical analysis of those differences.
The research team concluded that polypeptide-based emulsions could offer an effective delivery method for CBD in topical products, although additional studies involving human volunteers will be necessary to determine whether the improvements observed in laboratory models translate into clinical benefits.










